Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD38-SADA:177Lu-DOTA
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD38-SADA:177Lu-DOTA is an investigational two-step pretargeted radioimmunotherapy designed for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). The therapy uses a bispecific fusion protein, CD38-SADA, which tightly binds to the cell surface antigen CD38 and to radionuclides chelated to DOTA (tetraxetan). The SADA platform enables self-assembly into tetramers that have high avidity for tumor-associated CD38. In the first step, non-radiolabeled-CD38-SADA tetramers are administered and bind selectively to tumors expressing CD38; unbound protein disassembles into monomers cleared by the kidneys. In the second step, a radiolabeled payload (^177Lu chelated by DOTA) is infused and binds specifically to tumor-localized SADA proteins, delivering targeted irradiation while minimizing off-target toxicity. This approach aims for improved efficacy and safety compared to conventional radioimmunotherapies. The drug is being developed by Y-mAbs Therapeutics[1][3][4][5][6].
- Other names
- CD38-SADA PRIT with Lu177-DOTACD-38-SADA PRIT with Lu177-DOTACD 38-SADA PRIT with Lu177-DOTACD38-SADA:177Lu-DOTA Complex
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on CD38-SADA:177Lu-DOTA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD38-SADA:177Lu-DOTA.